Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Publication|Articles|June 12, 2025
Pharmacy Practice in Focus: Oncology
- June 2025
- Volume 7
- Issue 4
OPC 2025: You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment
Fact checked by: Gillian McGovern, Editor
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Advertisement
Advertisement
The increasing use of herbal supplements among patients undergoing cancer treatment, particularly those on oral therapies, presents a significant and often unaddressed challenge in oncology care. Despite the potential for harmful drug-herb interactions that can compromise treatment efficacy and patient safety, many patients do not disclose their supplement use to their health care providers.
Related to this article
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Advertisement
Advertisement